Date: 29 Nov 2007
Development of new targeted therapies for breast cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Clinical application of truly targeted therapy relies on identification of a specific molecular feature (the target) that is biologically relevant, reproducibly measurable and definably correlated with clinical benefit. Ideally the target should be crucial to the tumor’s malignant phenotype. The target must be easily measurable in readily obtained clinical samples. Interruption, interference or inhibition of the target should yield a clinical response in a significant proportion of patients whose tumors express the target but in few patients whose tumors do not express the target. As such, targeted therapy offers the twin hopes of maximizing efficacy while minimizing toxicity. A critical review of the hallmarks of malignancy provides a framework for considering potential targets and novel therapeutic interventions. The hallmarks of malignancy include uncontrolled proliferation, insensitivity to negative growth regulation, evasion of apoptosis, lack of senescence, invasion and metastasis, angiogenesis, and genomic elasticity. Existing therapies predominantly target proliferation either with cytotoxic agents, ionizing radiation or inhibition of estrogen receptor and HER2 growth factor signaling pathways. Further improvements in therapy must attack the other hallmarks of malignancy and will undoubtedly be accompanied by better means of individual patient selection for such therapies. Indeed, each of these hallmarks presents a therapeutic opportunity. To believe otherwise would be to assume that a feature is both biologically crucial yet therapeutically unimportant, an unlikely paradox.
This article is based on a keynote address of Symposium 3, “Molecular target therapy: basics and clinical application,” held on 30 June 2007 at the 15th Annual Meeting of the Japanese Breast Cancer Society in Yokohama.
Beaston G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104–7.
Jensen E, DeSombre E, Jungblut P. Estrogen receptors in hormone responsive tissues and tumors. Chicago: University of Chicago Press; 1969.
Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol. 1989;9:1165–72.PubMed
Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994;9:1829–38.PubMed
Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer: first planned interim efficacy analysis (abstract 1), 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. 2005.
Blackwell K, Kaplan E, Franco S, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol. 2004;22:abstr 3006.
Burstein H, Storniolo A, Franco S, et al. A phase II, open-label, multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol. 2004;15(suppl 3).
Kaplan E, Jones C, Berger M, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. 2003;22. Proc Am Soc Clin Oncol. 2003;22:abstr 981.
Blackwell K, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol. 2005;24:abstr 3004.
Spector N, Blackwell K, Hurley J, et al. EGF 103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Proc Am Soc Clin Oncol. 2006;25:abstr 502.
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;85:1182–6.
Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963–9.PubMed
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrinol Rev 1997, 1997.
Cobleigh M, Miller K, Langmuir V, et al. Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breat Cancer Res Treat. 2001;69:301.
Miller K, Burstein H, Elias A, et al. Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor in patients with previously treated metastatic breast cancer. Breast Cancer Res and Treat. 2005;95(Suppl 1):abstr 1006.
Chow L, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res and Treat 2006;100(Suppl 1):S286.
Mueller C, Riese U, Kosmehl H, et al. Telomerase activity in microdissected human breast cancer tissues: association with p53, p21 and outcome. Int J Oncol. 2002;20(2):385–90.PubMed
Shpitz B, Zimlichman S, Zemer R, et al. Telomerase activity in ductal carcinoma in situ of the breast. Breast Cancer Res and Treat. 1999;58:65–9.CrossRef
Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:452–9.PubMed
Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res. 1999;59:5917–21.PubMed
Wang Z, Kyo S, Takakura M, et al. Progesterone regulates human telomerase reverse transcriptase gene expression via activation of mitogen-activated protein kinase signaling pathway. Cancer Res. 2000;60:5376–81. PubMed
Izbicka E, Wheelhouse R, Raymond Eea. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res. 1999;59:639–44.
Muller A, Saretzki G, von Zglinicki T, et al. Telomerase inhibition by induced expression of antisense RNA. Adv Exp Med Biol. 1998;451:23–6.PubMed
Ludwig A, Saretzki G, Holm PS, et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res. 2001;61:3053–61.PubMed
Kossakowska AE, Huchcroft SA, Urbanski SJ, et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin’s lymphomas in humans. Br J Cancer. 1996;73:1401–8.PubMed
Monteagudo C, Merino MJ, San-Juan J, et al. Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol. 1990;136:585–92.PubMed
Zucker S, Lysik RM, Zarrabi MH, et al. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res. 1993;53:140–6.PubMed
Bramhall S, Rosemurgy A, Brown P, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447–55.PubMed
Shepard F, Giaccone G, Debruyne C, et al. Randomized double-blind placebo-controlled trial of marimastat in paitents with small cell lung cancer following response to first-line chemotherapy: an NCIC-CTG and EORTC study. Proc Am Soc Clin Oncol. 2001;20:4a.
Sparano JA, Bernardo P, Gradishar W, et al. Randomized phase II trial of marimastati versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial (E2196). Proc Am Soc Clin Oncol. 2002;21:44a.
- Development of new targeted therapies for breast cancer
Volume 15, Issue 1 , pp 49-56
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Growth factor
- Industry Sectors